Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update

Eyenovia, Inc.

Announced FDA approval of and first commercial sale of Mydcombi™, the only fixed dose combination of tropicamide and phenylephrine for mydriasis and the first FDA approved product to utilize the Optejet^®

Continued to advance its Phase 3 Apersure™ (Microline) presbyopia candidate following receipt of guidance from FDA that establishes an efficient path forward for the program

Company to host conference call and webcast today, August 10, at 4:30 pm ET

NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray) for mydriasis and developing the Optejet^® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced its financial and operating results for the second quarter ended June 30, 2023.

Second Quarter 2023 and Recent Business Developments

• Announced first commercial sale of Mydcombi to world-renowned board-certified ophthalmologist Dr. Nathan M. Radcliffe, who becomes first to incorporate Mydcombi into his daily practice. The company will be following up with sales to key physicians in the upcoming weeks and preparing for national launch in early 2024.

• Advanced its pre-NDA presbyopia program, Apersure (Microline), and anticipates commencing the manufacture of registration batches in the fourth quarter of 2023.

• Continued to build out its manufacturing facilities in Redwood City, CA and Reno, NV, the former having a PDUFA date in November 2023 for use as a commercial facility.

• Delivered presentation at the annual OCTANE Ophthalmology Tech Forum 2023 reviewing the recent FDA approval of Mydcombi.

• Licensing partners Bausch+Lomb and Arctic Vision continued to enroll patients in their respective Phase 3 studies of Micropine (US and China) and Microline (China).

• Announced addition to widely followed Russell 2000 and Russell 3000 Indexes.

Michael Rowe, Chief Executive Officer, commented, “We achieved very significant milestones since our last quarterly update, notably the FDA approval and first commercial sale of Mydcombi, officially transitioning us to a commercial stage company. We are now executing a targeted launch of Mydcombi while in parallel ramping up our internal manufacturing capabilities in anticipation of a broader campaign incorporating our Gen 2 Optejet device beginning in 2024.

"Regarding our pre-NDA presbyopia candidate, Apersure, we continue to advance this important program following receipt of feedback from FDA that established a clear and efficient path forward. The addressable presbyopia market for topical ophthalmic medications is a nearly one-billion-dollar market opportunity in the US alone, and we believe an effective solution that leverages our novel Optejet drug delivery platform and fits within the business model of optometrists will be highly differentiated in the marketplace. We plan to initiate the manufacture of registration batches of Apersure during the fourth quarter.

“We believe the approval and commercial availability of Mydcombi will fundamentally transform the way that topical eye drugs are developed and delivered, as we now have critical validation of our Optejet platform that will benefit not only our proprietary development programs, most notably Apersure, but current and future partnerships as well. To that end, we continue to have very productive discussions with potential partners that could ultimately see the Optejet incorporated into additional large market ophthalmology indications with persistent unmet needs.

“I am extremely pleased with our progress to date and look forward to a productive back half of the year,” Mr. Rowe concluded.

Second Quarter 2023 Financial Review

For the second quarter of 2023, net loss was approximately $(6.2) million, or $(0.16) per share compared to a net loss of approximately $(7.2) million, or $(0.22) per share, for the second quarter of 2022.

Research and development expenses totaled approximately $2.8 million for the second quarter of 2023 as compared to $3.6 million for the second quarter of 2022.

For the second quarter of 2023, general and administrative expenses were approximately $3.1 million, compared to $3.5 million for the second quarter of 2022.

Total operating expenses for the second quarter of 2023 were approximately $6.0 million compared to $7.1 million for the second quarter of 2022.

As of June 30, 2023, the Company’s cash and cash equivalents were approximately $17.5 million compared to $22.9 million as of December 31, 2022.

Conference Call and Webcast

The conference call is scheduled to begin at 4:30 pm ET today, August 10. Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international), and reference conference ID 13739696.

To access the Call me™ feature, which avoids having to wait for an operator, click here.

A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.eyenovia.com. After the live webcast, the event will be archived on Eyenovia’s website for one year.

IMPORTANT SAFETY INFORMATION for MYDCOMBI™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5%

INDICATIONS

MYDCOMBI is indicated to induce mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired

CONTRAINDICATIONS: In patients with known hypersensitivity to any component of the formulation

WARNINGS AND PRECAUTIONS

FOR TOPICAL OPHTHALMIC USE. NOT FOR INJECTION
This preparation may cause CNS disturbances which may be dangerous in pediatric patients. The possibility of psychotic reaction and behavioral disturbance due to hypersensitivity to anticholinergic drugs should be considered.
Mydriatics may produce a transient elevation of intraocular pressure.
Significant elevations in blood pressure have been reported. Caution in patients with elevated blood pressure.
Rebound miosis has been reported one day after installation.
Remove contact lenses before using.

DRUG INTERACTIONS

Atropine-like Drugs: May exaggerate the adrenergic pressor response
Cholinergic Agonists and Ophthalmic Cholinesterase Inhibitors: May interfere with the antihypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors
Potent Inhalation Anesthetic Agents: May potentiate cardiovascular depressant effects of some inhalation anesthetic agents

ADVERSE REACTIONS

• Most common ocular adverse reactions include transient blurred vision, reduced visual acuity, photophobia, superficial punctate keratitis, and mild eye discomfort. Increased intraocular pressure has been reported following the use of mydriatics.

• Systemic adverse reactions including dryness of the mouth, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, central nervous system disturbances and muscle rigidity have been reported with the use of tropicamide.

To report SUSPECTED ADVERSE REACTIONS, contact Eyenovia, Inc. At 1-833-393-6684 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch)

Please go to www.mydcombi.com for FULL PRESCRIBING INFORMATION

About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics. Eyenovia is currently focused on the commercialization of Mydcombi and the late-stage development of microdosed medications for presbyopia and myopia progression. For more information, visit www.eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

Forward-Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our products, product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment, timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential impacts of any disruptions on our supply chain, including the availability of sufficient components and materials used in our products and product candidates; the potential advantages of our products, product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our products and product candidates; our estimates regarding the potential market opportunity for our products and product candidates; reliance on third parties to develop and commercialize our products and product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our products and product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; our competitive position; and other risks described from time to time in the “Risk Factors” section of our filings with the U.S. Securities and Exchange Commission, including those described in our Annual Report on Form 10-K as well as our Quarterly Reports on Form 10-Q, and supplemented from time to time by our Current Reports on Form 8-K. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.

Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com

Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363

Eyenovia Media Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com

EYENOVIA, INC.
Condensed Balance Sheets
				June 30,				December 31,
				2023				2022
				(unaudited)
Assets
											=
Current Assets
	Cash and cash equivalents			$	17,468,088			$	22,863,520
	Deferred clinical supply costs				3,578,326				2,284,931
	License fee and expense reimbursements receivable				429,006				1,183,786
	Security deposits, current				-				119,550
	Prepaid expenses and other current assets				1,801,373				1,190,719
		Total Current Assets			23,276,793				27,642,506
Property and equipment, net					3,698,421				1,295,115
Security deposits, non-current					198,674				80,874
Operating lease right-of-use asset					1,915,061				1,291,592
Equipment deposits					257,950				726,326
		Total Assets		$	29,346,899			$	31,036,413
Liabilities and Stockholders' Equity
Current Liabilities:
	Accounts payable			$	1,312,749			$	1,428,283
	Accrued compensation				1,013,118				1,747,191
	Accrued expenses and other current liabilities				363,431				503,076
	Operating lease liabilities - current portion				427,749				484,882
	Notes payable - current portion, net of debt discount of $91,621
	and $33,885 as of June 30, 2023 and December 31, 2022, respectively				947,163				174,448
	Convertible notes payable - current portion, net of debt discount of $0
	and $33,885 as of June 30, 2023 and December 31, 2022, respectively				-				174,448
		Total Current Liabilities			4,064,210				4,512,328
Operating lease liabilities - non-current portion					1,584,218				907,644
Notes payable - non-current portion, net of debt discount of $1,120,372
and $813,229 as of June 30, 2023 and December 31, 2022, respectively					8,683,794				4,190,938
Convertible notes payable - non-current portion, net of debt discount of $507,270
and $813,229 as of June 30, 2023 and December 31, 2022, respectively					4,492,730				4,190,938
		Total Liabilities			18,824,952				13,801,848
Stockholders' Equity:
	Preferred stock, $0.0001 par value, 6,000,000 shares authorized;
	0 shares issued and outstanding as of June 30, 2023 and
	December 31, 2022				-				-
	Common stock, $0.0001 par value, 90,000,000 shares authorized;
	38,169,398 and 36,668,980 shares issued and outstanding
	as of June 30, 2023 and December 31, 2022, respectively				3,817				3,667
	Additional paid-in capital				140,703,819				135,461,361
	Accumulated deficit				(130,185,689	)			(118,230,463	)
		Total Stockholders' Equity			10,521,947				17,234,565
		Total Liabilities and Stockholders' Equity		$	29,346,899			$	31,036,413

 

EYENOVIA, INC.
Condensed Statements of Operations
(unaudited)
			For the Three Months Ended								For the Six Months Ended
			June 30,								June 30,
			2023				2022				2023				2022
Operating Expenses:
	Research and development		$	2,811,061			$	3,586,866			$	5,333,011			$	7,299,450
	General and administrative			3,149,809				3,534,590				6,086,695				7,009,555
		Total Operating Expenses		5,960,870				7,121,456				11,419,706				14,309,005
		Loss From Operations		(5,960,870	)			(7,121,456	)			(11,419,706	)			(14,309,005	)
Other Income (Expense):
	Other income, net			119,450				33,376				190,443				26,303
	Interest expense			(558,003	)			(153,436	)			(1,012,006	)			(298,673	)
	Interest income			183,563				2,416				286,043				2,610
		Net Loss	$	(6,215,860	)		$	(7,239,100	)		$	(11,955,226	)		$	(14,578,765	)
Net Loss Per Share - Basic and Diluted			$	(0.16	)		$	(0.22	)		$	(0.32	)		$	(0.46	)
Weighted Average Number of Common
	Shares Outstanding
		- Basic and Diluted		38,093,826				33,644,867				37,753,694				31,836,582